Logo
Logo


ISSN: 0300-9041
ISSNe: 2594-2034


Indizada en: SciELO, Índice Médico Latinoamericano, LILACS, Medline
Editada por la Federación Mexicana de Colegios de Obstetricia, y Ginecologia AC
Fundada por la Asociación Mexicana de Ginecología y Obstetricia en 1945
 

INFORMACIÓN EXCLUSIVA PARA LOS PROFESIONALES DE LA SALUD


Periodicidad: continua
Abreviatura: Ginecol Obstet Mex
ISSN: 0300-9041
ISSNe: 2594-2034
Indizada en: Scimago, Índice Médico Latinoamericano, Lilacs, Medline, Science Citation Index, Ulrich, Ebsco.

Artritis reumatoide y embarazo. Reporte de un caso y revisión de la bibliografía

Rheumatoid arthritis and pregnancy. A case report and literature review.

Ginecol Obstet Mex. 2020; 88 (11): 806-814.

https://doi.org/10.24245/gom.v88i11.4230

Carlos Santiago Piñel-Pérez,1 María José Gómez-Roso Jareño,2 Constanza Gabriela Caliendo,2 Gizelle Helena Steinberg-Contreras,2 Juan José López-Galián3

1 Adjunto al servicio de Obstetricia y Ginecología, profesor asociado de Obstetricia y Ginecología.
2 Adjunto al servicio de Obstetricia y Ginecología, profesora colaboradora de Obstetricia y Ginecología.
3 Jefe del servicio de Obstetricia y Ginecología, profesor asociado de Obstetricia y Ginecología.
Universidad Europea de Madrid, España; Hospital Quirónsalud San José, Madrid, España.


Corrrespondencia:

Carlos Santiago Piñel Pérez
carlos.s.pinel@gmail.com

Debe citarse como:

Piñel-Pérez CA, Gómez-Roso Jareño MJ, Caliendo CG, Steinberg-Contreras GH, López-Galián JJ. Artritis reumatoide y embarazo. Reporte de un caso y revisión de la bibliografía. Ginecol Obstet Mex. 2020; 88 (11): 806-814. https://doi.org/10.24245/gom.v88i11.4230

Resumen

ANTECEDENTES: La artritis reumatoide suele evolucionar durante el embarazo e, incluso, en un porcentaje importante de pacientes permanece activa. En estos casos se ha reportado elevación del riesgo de complicaciones (aborto del primer trimestre, prematuridad, preeclampsia y restricción del crecimiento intrauterino) y mayor posibilidad de cesárea.

CASO CLÍNICO: Paciente de 40 años, primigesta, con diagnóstico previo de artritis reumatoide en remisión, que logró el embarazo después de nueve ciclos de transferencia embrionaria, permaneció en tratamiento con glucocorticoides, hidroxicloroquina y adalimumab. El embarazo transcurrió sin complicaciones obstétricas ni brotes de artritis reumatoide. Se suspendió la hidroxicloroquina y adalimumab en la semana 20. Se llevó a cabo la cesárea en la semana 39 debido al fracaso de la inducción del parto. Se obtuvo un recién nacido sano, de 3095 g, con pH de la arteria umbilical de 7.27 y Apgar 9-10. El puerperio transcurrió sin complicaciones médicas ni obstétricas.

CONCLUSIONES: En mujeres con artritis reumatoide, la planificación del embarazo es importante porque debe iniciarse en el periodo de remisión de la enfermedad. Las complicaciones obstétricas se asocian con embarazos que se inician en la fase activa de la artritis reumatoide. El tratamiento con glucocorticoides (hidroxicloroquina y anti-TNF) en dosis bajas durante el primer trimestre del embarazo ha demostrado seguridad para la madre y el feto, y eficacia para mantener la enfermedad en remisión.

PALABRAS CLAVE: Artritis reumatoide; embarazo; cesárea; transferencia de embriones; arteria umbilical; adalimumab; hidroxicloroquina; fármacos anti-TNF.

Abstract

BACKGROUND: The course of rheumatoid arthritis generally improves during pregnancy, but there are a significant number of patients who maintain active disease. In these cases, an increased risk of complications (first trimester abortions, prematurity, pre-eclampsia and restricted intrauterine growth) has been reported, as well as a higher probability of cesarean section.

CASE REPORT: 40-year-old patient, in the first pregnancy, with a previous diagnosis of rheumatoid arthritis in remission who managed to obtain her pregnancy after nine embryo transfers, maintaining treatment with glucocorticoids, hydroxychloroquine, and adalimumab. Pregnancy went without obstetric complications or outbreaks of rheumatoid arthritis. Treatment with hydroxychloroquine and adalimumab was withdrawn at week 20. Cesarean section was performed at week 39 due to failure of induction. A healthy newborn of 3095 grams was obtained, who did not require neonatal resuscitation or admission to the neonatal intensive care unit. Obtained an umbilical artery pH of 7.27 and Apgar 9/10. The puerperium passed without medical or obstetric complications.

CONCLUSION: The planning of pregnancy is essential in women with rheumatoid arthritis, and should start in the period of remission of the disease. Obstetric complications are associated with pregnancies initiated in the active phase of rheumatoid arthritis. Treatment with low-dose glucocorticoids during the first phase of pregnancy (hydroxychloroquine, and anti-TNF biologic drugs) have shown maternal-fetal safety and efficacy in keeping the disease in remission.

KEYWORDS: Rheumatoid arthritis; Pregnancy; Cesarean section; Embryo transfer; Umbilical artery; Adalimumab; Hydroxychloroquine; Anti-TNF biological drugs.

    1. Lee DM, et al. Rheumatoid arthritis. Lancet 2001; 358 (9285): 903-11. doi: https://doi.org/10.1016/S0140-6736(01)06075-5
    2. Turrión-Nieves A, et al. Artritis reumatoide. Medicine 2017; 12 (28): 1615-25. doi: https://doi.org/10.1016/j.med.2017.02.010
    3. Crowson CS, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63 (3): 633-9. doi: https://doi.org/10.1002/art.30155
    4. Smolen JS, et al. Rheumatoid arthritis. Lancet 2016; 388 (10055): 2023-38. doi: https://doi.org/10.1016/S0140-6736(16)30173-8
    5. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs; 2013 update. Ann Rheum Dis 2014; 73 (3): 492-509. doi: https://doi.org/10.1136/annrheumdis-2013-204573
    6. Smeele HTW, et al. Current perspectives on fertility, pregnancy and childbirth in patients with Rheumatoid Arthritis. Semin Arthritis Rheum 2019; 49 (3S): S32-S35. doi: https://doi.org/10.1016/j.semarthrit.2019.09.010
    7. Fischer-Betz R, et al. Schwangerschaft bei rheumatischen erkrankungen. Z Rheumatol 2020; 79 (1): 55-73. doi: https://doi.org/10.1007/s00393-013-1223-9
    8. Maynard S, et al. Pregnancy in women with systemic lupus and lupus nephritis. Adv Chronic Kidney Dis 2019; 26 (5): 330-7. doi: https://doi.org/10.1053/j.ackd.2019.08.013
    9. Piñel-Pérez CS, et al. Poliarteritis con daño pulmonar (Churg-Strauss) y embarazo. Reporte de un caso y revisión bibliográfica. Ginecol Obstet Mex 2019; 87 (11): 756-61. doi: https://doi.org/10.24245/gom.v87i11.3329
    10. Brouwer J, et al. Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis 2015; 74 (10): 1836-41. doi: https://doi.org/10.1136/annrheumdis-2014-205383
    11. Norgaard BM, et al. Decreased chance of a live born child in women with rheumatoid arthritis after assisted reproduction treatment: a nationwide cohort study. Ann Rheum Dis 2019; 78 (3): 328-34. doi: https://doi.org/10.1136/annrheumdis-2018-214619
    12. Förger F, et al. Immunological adaptations in pregnancy that modulate rheumatoid arthritis disease activity. Nat Rev Rheumatol 2020; 16 (2): 113-22. doi: https://doi.org/10.1038/s41584-019-0351-2
    13. Jethwa H, et al. Does rheumatoid arthritis really improve during pregnancy? A systematic review and meta-analysis. J Rheumatol 2019; 46 (3): 245-50. doi: https://doi.org/10.3899/jrheum.180226
    14. Norgaard M, et al. Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J Intern Med 2010; 268 (4): 329-37. doi: https://doi.org/10.1111/j.1365-2796.2010.02239.x
    15. De Jong P, et al. Fertility, pregnancy and lactation in rheumatoid arthritis. Rheum Dis Clin North Am 2017; 43 (2): 227-37. doi: 10.1016/j.rdc.2016.12.004 (https://www.rheumatic.theclinics.com/article/S0889-857X(16)30107-7/fulltext)
    16. Kishore S, et al. Obstetric outcomes in women with rheumatoid arthritis: results from nationwide inpatient sample database 2003-2011. Semin Arthritis Rheum 2019; 49 (2): 236-40. doi: https://doi.org/10.1016/j.semarthrit.2019.03.011
    17. Ince-Askan H, et al. Pregnancy and rheumatoid arthritis. Best Pract Res Clin Rheumatol 2015; 29 (4-5): 580-96. doi: https://doi.org/10.1016/j.berh.2015.07.001
    18. Brouwer J, et al. Brief Report: Miscarriages in female rheumatoid arthritis patients: associations with serologic findings, disease activity and antirheumatic drug treatment. Arthritis Rheumatol 2015; 67 (7): 1738-43. doi: https://doi.org/10.1002/art.39137
    19. Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Curr Opin Rheumatol 2014; 26 (3): 334-40. doi: https://doi.org/10.1097/BOR.0000000000000054
    20. Birru Talabi M, et al. Antirheumatic medications in pregnancy and breastfeeding. Curr Opin Rheumatol 2020; 32 (3): 238-46. doi: https://doi.org/10.1097/BOR.0000000000000710
    21. Alijotas-Reig J, et al. Tratamiento de las gestantes con enfermedades reumáticas o autoinmunitarias sistémicas con fármacos inmunodepresores y biológicos. Med Clin 2016; 147 (8): 352-60. doi: https://doi.org/10.1016/j.medcli.2016.05.020
    22. Nguyen GC, Jones J et al. IBD in pregnancy consensus group; Canadian Association of Gastroenterology. The Toronto Consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterol 2016; 150 (3): 734-57. doi: https://doi.org/10.1053/j.gastro.2015.12.003
    23. Chaudrey KH, et al. Safety of immunomodulators and anti-TNF therapy in Pregnancy. Curr Trat Options Gastroenterol 2015; 13 (1): 77-89. doi: https://doi.org/10.1007/s11938-014-0037-4
    24. Mahadevan U, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11 (3): 286-92; quiz e24. doi: https://doi.org/10.1016/j.cgh.2012.11.011
    25. Chaparro M, et al. Long-term safety of in utero exposure to anti-TNFalfa drugs for the treatment of infmammatory bowel disease: results from the multicenter European TEDDY Study. Am J Gastroenterol 2018; 113 (3): 396-403. doi: https://doi.org/10.1038/ajg.2017.501
    26. Gotestam Skorpen C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, during pregnancy and lactation. Ann Rheum Dis 2016; 75 (5): 795-810. doi: https://doi.org/10.1136/annrheumdis-2015-208840
    27. Iranzo González-Cruz I, Gil Borrás R, Martín Arranz MD, García Corbalán MJ, Jaén Revuelta M. Uso de adalimumab durante la gestación en la enfermedad de Crohn. Enferm Inflam Intest Día. 2017; 16 (3): 158-62. doi: https://doi.org/10.1016/j.eii.2016.12.005
    28. Chambers CD, et al. Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study. PLoS One 2019; 14 (10): e0223603. doi: https://doi.org/10.1371/journal.pone.0223603
    29. APILAM. Asociación para la promoción e investigación científica y cultural de la lactancia materna; 2002. http://e-lactancia.org

Comentarios